|Articles|February 8, 2004
Enbrel manufacturer speaks of post-approval plan
Washington, D.C. Officials of Amgen spoke of teaching patientsabout biologic treatments of psoriasis, dermatologists spreading the wordabout the new class of drugs, and the physician-patient relationship asits Enbrel (etanercept) added to the resume leading it toward approval bythe U.S. Food and Drug Administration.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
The Weekly Roundup: January 12-16
3
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5














